Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > Subgroup analysis VOYAGER PAD

Subgroup analysis VOYAGER PAD

Presented By
Prof. W. Hiatt, University of Colorado, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACC 2020
Trial
VOYAGER PAD
A prespecified subgroup analysis of VOYAGER PAD demonstrated that background clopidogrel in patients with peripheral artery disease (PAD) receiving rivaroxaban and low-dose aspirin after lower extremity revascularisation does not modify the benefit of rivaroxaban but appears to increase bleeding [1]. The VOYAGER PAD trial was the largest evidence base of patients with revascularised symptomatic PAD, which demonstrated that the combination of twice-daily rivaroxaban and once-daily aspirin was safe and more effective than aspirin alone for reducing future thrombotic and ischaemic events [2]. In the current subgroup analysis of VOYAGER PAD, presented by Prof. William Hiatt (University of Colorado, USA), investigators aimed to evaluate whether efficacy and safety of rivaroxaban were consistent regardless of background clopid...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on